One pill to tackle diabetes and cholesterol? new trial underway

NCT ID NCT04602754

Recruiting now Disease control Sponsor: EMS Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests a new combination pill called Berlim 25/20, which contains two medicines: empagliflozin (for diabetes) and rosuvastatin (for cholesterol). The study aims to see if this single pill can better control blood sugar and LDL cholesterol in people with type 2 diabetes and high cholesterol. About 228 adults are being recruited across multiple centers in a double-blind, randomized design.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Berlim 25/20 (a combination of empagliflozin and rosuvastatin)
What this could lead to: If successful, this could provide a single-pill option to manage both blood sugar and cholesterol in people with type 2 diabetes.
What could go wrong: This is a phase 3 trial, but results are not yet available. The combination may not prove more effective than existing separate treatments, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias inherited lipid metabolism disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DYSLIPIDEMIA ASSOCIATED WITH TYPE II DIABETES MELLITUS

Contacts and locations

Locations

Allergisa
RECRUITING

Campinas, São Paulo, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.